These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 1376392)

  • 1. Purification and characterization of heterologous component IIs of botulinum C2 toxin.
    Ohishi I; Hama Y
    Microbiol Immunol; 1992; 36(3):221-9. PubMed ID: 1376392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneities of two components of C2 toxin produced by Clostridium botulinum types C and D.
    Ohishi I; Okada Y
    J Gen Microbiol; 1986 Jan; 132(1):125-31. PubMed ID: 3086490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of botulinum C2 toxin by trypsin.
    Ohishi I
    Infect Immun; 1987 Jun; 55(6):1461-5. PubMed ID: 3570475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification and characterization of two components of botulinum C2 toxin.
    Ohishi I; Iwasaki M; Sakaguchi G
    Infect Immun; 1980 Dec; 30(3):668-73. PubMed ID: 6785232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of tissue-cultured cynomolgus monkey kidney cells to botulinum C2 toxin.
    Miyake M; Ohishi I
    Microb Pathog; 1987 Oct; 3(4):279-86. PubMed ID: 3332909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAD-glycohydrolase activity of botulinum C2 toxin: a possible role of component I in the mode of action of the toxin.
    Ohishi I
    J Biochem; 1986 Aug; 100(2):407-13. PubMed ID: 3023308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic similarity of toxins produced by Clostridium botulinum type C and D strains.
    Oguma K; Syuto B; Iida H; Kubo S
    Infect Immun; 1980 Dec; 30(3):656-60. PubMed ID: 6785231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADP-ribosylation of nonmuscle actin with component I of C2 toxin.
    Ohishi I; Tsuyama S
    Biochem Biophys Res Commun; 1986 Apr; 136(2):802-6. PubMed ID: 3518719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homogeneity and heterogeneity of toxins produced by Clostridium botulinum type C and D strains.
    Oguma K; Syuto B; Agui T; Iida H; Kubo S
    Infect Immun; 1981 Nov; 34(2):382-8. PubMed ID: 6171518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Production of monospecific type A botulinum toxin and antiserum using a column chromatographic method].
    Marchev N; Marcheva D
    Vet Med Nauki; 1982; 19(1):57-63. PubMed ID: 6810534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antigenicity of toxins produced by Clostridium botulinum type C and D strains.
    Ochanda JO; Syuto B; Oguma K; Iida H; Kubo S
    Appl Environ Microbiol; 1984 Jun; 47(6):1319-22. PubMed ID: 6204594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of Clostridium botulinum type E toxin purified by two different procedures.
    Yokosawa N; Tsuzuki K; Syuto B; Oguma K
    J Gen Microbiol; 1986 Jul; 132(7):1981-8. PubMed ID: 2432159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification and properties of Clostridium botulinum type F toxin.
    Yang KH; Sugiyama H
    Appl Microbiol; 1975 May; 29(5):598-603. PubMed ID: 807160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of phagocytosis by rainbow trout (Oncorhynchus mykiss) macrophages by botulinum C2 toxin and its trypsinized component II.
    Kodama H; Baba T; Ohishi I
    Dev Comp Immunol; 1994; 18(5):389-95. PubMed ID: 7698363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular permeability activity of botulinum C2 toxin elicited by cooperation of two dissimilar protein components.
    Ohishi I; Iwasaki M; Sakaguchi G
    Infect Immun; 1981 Mar; 31(3):890-5. PubMed ID: 7014465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and some properties of progenitor toxins of Clostridium botulinum type B.
    Kozaki S; Sakaguchi S; Sakaguchi G
    Infect Immun; 1974 Oct; 10(4):750-6. PubMed ID: 4214781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid method for purification of Clostridium botulinum type C neurotoxin by high performance liquid chromatography (HPLC).
    Matsuda M; Ozutsumi K; Du PY; Sugimoto N
    Eur J Epidemiol; 1986 Dec; 2(4):265-71. PubMed ID: 3542554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Isolation and properties of highly purified C1. botulinum toxin type E].
    Levdikova GA; Klimacheva LV; Ispolatovskaia MV; Bulatova TI; Anisimova LI
    Biokhimiia; 1979 Aug; 44(8):1392-400. PubMed ID: 115504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and molecular size of Clostridium botulinum type C toxin.
    Syuto B; Kubo S
    Appl Environ Microbiol; 1977 Feb; 33(2):400-5. PubMed ID: 403861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clostridium botulinum type D toxin: purification, molecular structure, and some immunological properties.
    Miyazaki S; Iwasaki M; Sakaguchi G
    Infect Immun; 1977 Aug; 17(2):395-401. PubMed ID: 892912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.